BioCentury
ARTICLE | Clinical News

CASI reports Phase II data for ENMD-2076 in clear cell ovarian cancer

June 2, 2017 7:18 PM UTC

In an abstract released ahead of the American Society of Clinical Oncology meeting in Chicago, CASI Pharmaceuticals Inc. (NASDAQ:CASI) reported data from 37 evaluable patients with recurrent clear cell ovarian cancer in a Phase II trial showing that once-daily 275 mg oral ENMD-2076 led to 2 partial responses, plus 25 cases of stable disease. Median progression-free survival (PFS) was 3.7 months and the estimated 6-month PFS rate was 20%. In patients with AT rich interactive domain 1A (ARID1A) loss (n=19), median PFS was 4.1 months and the estimated 6-month PFS rate was 31%. In ARID1A-positive patients (n=17), median PFS was 3.6 months and the estimated 6-month PFS rate was 12%. ENMD-2076 was well tolerated.

The open-label, Canadian trial is evaluating 6-month PFS rate and overall response rate (ORR) as its co-primary endpoints. Secondary endpoints include duration of response, biomarkers and safety...